Prospective Cohort Study of the Clinical Applications for the Pathologic Type, Staging, and Grading of GIST
1 other identifier
observational
900
1 country
1
Brief Summary
Evaluate the reliability of morphology standards for GIST pathologic type, staging and grading by retrospective analyzing clinical data; on this basis, establish a GIST standardized and individualized treatment mode to maximum benefit GIST patients, avoid under- and over-treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2013
CompletedFirst Submitted
Initial submission to the registry
January 17, 2015
CompletedFirst Posted
Study publicly available on registry
February 2, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2016
CompletedFebruary 2, 2015
January 1, 2015
3.2 years
January 17, 2015
January 28, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Number of participants with tumor recurrence
3 years
Number of participants with tumor metastasis
3 years
Study Arms (2)
Treatment observation group
According to the morphological criteria, the NIH scheme, and the WHO standard, GIST patients are divided into two groups, benign group and malignant group. In fully informed of their illness, patients are free to choose the sequence treatments according to their own gene mutation status and economic conditions. Patients who choose postoperative Imatinib treatment are labeled treatment group.
Control observation group
According to the morphological criteria, the NIH scheme, and the WHO standard, GIST patients are divided into two groups, benign group and malignant group. In fully informed of their illness, patients are free to choose the sequence treatments according to their own gene mutation status and economic conditions. Patients who choose no Imatinib treatment are labeled observation group.
Interventions
The patients were followed up for 3 years about their survival conditions and tumor status (eg. recurrence and metastasis).
Eligibility Criteria
patients diagnosed with GIST by pathology
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Sponsors & Collaborators
Study Sites (1)
180 Fenglin Road
Shanghai, Shanghai Municipality, 200032, China
Biospecimen
GIST paraffin specimens
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Yingyong Hou, Doctor
Shanghai Zhongshan Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 17, 2015
First Posted
February 2, 2015
Study Start
July 1, 2013
Primary Completion
September 1, 2016
Last Updated
February 2, 2015
Record last verified: 2015-01